Ionis Pharmaceuticals (IONS) Net Margin (2009 - 2026)

Ionis Pharmaceuticals' Net Margin history runs 18 years deep, the most recent figure standing at 42.79% for Q2 2026.

• In Q2 2026, Net Margin fell 7012.0% year-over-year to 42.79%; the TTM figure through Jun 2026 stood at 31.3% (down 1240.0% YoY), while the FY2025 annual figure was 31.94%, up 1969.0% from the prior year.
• Net Margin for Q2 2026 stood at 42.79%, up from 185.06% in the prior quarter.
• The five-year high for Net Margin was 60.76% in Q4 2025, with the low at 185.06% in Q1 2026.
• The 5-year median for Net Margin is 45.59% (2022), against an average of 52.97%.
• The sharpest annual moves came in 2025 and 2026: Net Margin jumped 6719 bps in 2025, then plunged 7341 bps in 2026.
• Ionis Pharmaceuticals' Net Margin stood at 8.54% in 2022, then jumped by 233 bps to 28.49% in 2023, then plunged by 123 bps to 6.43% in 2024, then soared by 1045 bps to 60.76% in 2025, then slumped by 170 bps to 42.79% in 2026.
• Business Quant data shows IONS's Net Margin at 42.79% in Q2 2026, 185.06% in Q1 2026, and 60.76% in Q4 2025.